No Data
US Stock MarketDetailed Quotes
NAVB Navidea Biopharmaceuticals
Watchlist
0.0920
+0.0018+2.00% Close 05/31 16:00 ET
0.0937+0.0017+1.85%
Pre 08:24 ET
0.0934High0.0862Low3.13MVolume
0.0901Open0.0902Pre Close285.50KTurnover12.30%Turnover RatioLossP/E (TTM)3.23MMarket Cap1.050052wk HighLossP/E (Static)35.06MShares0.082552wk Low-0.33P/B2.34MFloat Cap364.9998Historical High--Dividend TTM25.44MShs Float0.0825Historical Low--Div YieldTTM7.98%Amplitude0.0910Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Company
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.
Revenue Breakdown
Business
Unit:USD
NameYOYOperating income%
Diagnostics--65.65K100.00%
News
Navidea Biopharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent App 17/370,920 Titled "Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans & Derivatives Thereof (For Tilmanocept Immunotherapeutic Applications)"
Navidea Biopharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent App 17/370,920 Titled "Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans & Derivatives Thereof (Fo
Express News | Navidea Biopharmaceuticals Sells Preferred Shares Worth $1.1 Million
Navidea Biopharmaceuticals Announced The Sale Of Preferred Shares Totaling $1.1M To New Existing Investors; It Provides Additional Capital To Fuel Navidea's NAV3-32 And NAV3-33 Trials Toward Completion
Navidea Biopharmaceuticals Announced The Sale Of Preferred Shares Totaling $1.1M To New Existing Investors; It Provides Additional Capital To Fuel Navidea's NAV3-32 And NAV3-33 Trials Toward Completio
Comments
news coming tomorrow
1
1
Read more